BiotechTube

Sonlicromanol + Placebo

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mitochondrial Diseases

Conditions

Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, MELAS, Subacute Necrotizing Encephalomyelopathy

Trial Timeline

Feb 1, 2021 → Dec 1, 2025

NCT ID
NCT04846036

About Sonlicromanol + Placebo

Sonlicromanol + Placebo is a phase 2 stage product being developed by Certara for Mitochondrial Diseases. The current trial status is active. This product is registered under clinical trial identifier NCT04846036. Target conditions include Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, MELAS.

What happened to similar drugs?

0 of 1 similar drugs in Mitochondrial Diseases were approved

Approved (0) Terminated (0) Active (1)
🔄VatiquinonePTC TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04846036Phase 2Active

Competing Products

13 competing products in Mitochondrial Diseases

See all competitors
ProductCompanyStageHype Score
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mgAbbViePhase 2
35
Cysteamine BitartrateAmgenPhase 2
27
Cysteamine BitartrateAmgenPhase 2
35
VatiquinonePTC TherapeuticsPhase 2/3
27
EPI-743PTC TherapeuticsPre-clinical
23
RG2133 (2',3',5'-tri-O-acetyluridine)RepligenPhase 1
18
VatiquinonePTC TherapeuticsPre-clinical
27
VatiquinonePTC TherapeuticsPhase 3
37
Oral administration of 100 mg KH176 twice dailyCertaraPhase 2
29